pharmaceutical industry

What pharmaceutical industry does

The input does not describe a single company but rather India's pharmaceutical industry sector. India is the third-largest pharmaceutical producer globally by volume and 14th by value, with a market size of approximately $50 billion. The industry supplies roughly 20% of global generic drug volumes by volume and fills 47% of US generic prescriptions, making it a structural pillar of affordable global healthcare. Revenue mechanics are dominated by export of finished generic formulations: $30.47 billion in FY24-25, growing 9.4% year-over-year, and $28.29 billion in April-February FY26 with 5% YoY growth. The US is the single largest export destination at 30.48% of exports. Operational geographies span India (manufacturing base), the United States (largest market), the Philippines, Denmark and Czechia. The competitive model is cost-leadership in small-molecule generics plus regulatory scale (FDA approvals). No specific proprietary technology, product mix, customer logos, or company-level financials are present in the source, so this description is necessarily at industry-aggregate level.

Name

pharmaceutical industry

Legal name

pharmaceutical industry

Website

https://heptopic.com

Company type

Private

Operating status

Operating

Short description

India's pharmaceutical sector produces low-cost generic medicines at scale, supplying roughly 20% of global generic drug volumes and 47% of US generic prescriptions, with $30.47B in FY24-25 exports concentrated in the US market.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Oral Solid Dose (OSD) Generics (HLAIABAD), Small-Molecule Generics (Branded/Unbranded) (HLAIABAA), Generic APIs & Intermediates (Active Ingredients) (HLAIABAG), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Generic drug manufacturing
• Pharmaceutical exports
• Active pharmaceutical ingredients
• Generic medications supply
• Finished dosage formulations

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Core offering

The entity, described at the sector level, involves the manufacture and export of generic pharmaceutical products and APIs. It supplies roughly 20% of global generic drug volumes by value of production and fulfills approximately 47% of US generic prescriptions. The reference site (heptopic.com/viraday) links to a generic antiretroviral combination product (Viraday), indicating finished generic dosage formulations as part of the offering mix.

Product overview

No specific product or service information available. The source data covers India's pharmaceutical industry broadly, including statistics on generic drug production (supplying ~20% of global generic drug volumes and 47% of US generic prescriptions), supply chain dependencies on China for APIs (60-70% sourced from China), and industry-wide challenges related to tariffs, trade disruptions, and regulatory pressures.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Pharmaceutical Products Generic medicines covering a broad therapeutic range, exported globally and supplied into the US generic prescription market (47% of US generic prescriptions). The referenced product page (heptopic.com/viraday) illustrates a generic antiretroviral combination (Viraday) offered to consumer/patient channels.
• Active Pharmaceutical Ingredients (APIs) Bulk drug substances and intermediates used as inputs for finished dosage formulations, both for captive use and B2B supply to other manufacturers.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Sun Pharmaceutical Industries: India's largest pharmaceutical company and a leading global generic manufacturer with significant US exposure — directly comparable as an Indian-headquartered generic FDF and API producer targeting the same US and emerging-market customers.
• Zydus Lifesciences: Indian integrated pharmaceutical company spanning APIs, formulations, and biosimilars — a directly comparable Indian generics and API exporter serving US and emerging markets.
• Cipla: Major Indian generic and API manufacturer with a strong US, Europe, and emerging-market franchise — directly comparable as an Indian generics exporter operating in the same regulatory and pricing environment.
• Dr. Reddy's Laboratories: India-headquartered generic and branded pharmaceutical company with a sizable US generics business — directly comparable for its India-based FDF manufacturing, API sourcing profile, and exposure to the same US tariff regime.
• Aurobindo Pharma: Indian generic and API manufacturer with one of the largest US generic footprints — directly comparable for its vertically integrated FDF + API model and its dependency on the same regulatory and tariff dynamics.
• Torrent Pharmaceuticals: Indian generic and specialty pharmaceutical company with US and Latin America operations — comparable as another India-based generics exporter with similar customer and regulatory exposure.
• Lupin Pharmaceuticals: Indian generic-drug manufacturer with significant US prescription business — directly comparable across finished-dose generics, API dependency, and US export exposure.

Broad incumbents

• Sandoz (Novartis): Global generics and biosimilars division spun out of Novartis — directly comparable as a large-scale generic FDF manufacturer competing in the same US and European channels as Indian exporters.
• Viatris: Global healthcare company formed from Mylan and Upjohn with a broad generics and biosimilars portfolio — competes with Indian generic exporters across US and global markets as a broader incumbent rather than an India-only specialist.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer and a broader incumbent in the same global generics space — overlaps directly with India's generic exporters in US tender and retail channels but at much greater scale and breadth.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about pharmaceutical industry